Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Social determinants of health shape treatment course and long term outcomes in patients with high-risk myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

NANatasha Amjed

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis connected social determinants to treatment outcomes in high-risk patients, emphasizing disparities in healthcare utilization and frailty.

Key Points

  • Long-term outcomes were significantly impacted by social determinants of health for patients with myeloproliferative neoplasms.
  • The odds of MI and stroke increased with poverty rate as shown by significant odds ratios of 1.019 and 1.025.
  • Retrospective cohort analysis highlighted disparities in healthcare utilization, with African Americans visiting clinical sites nearly twice as often as Whites.
  • These findings point to the need for enhanced focus on social risk factors for equitable care in hematologic conditions.

Cite This Study

Natasha Amjed (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe2https://doi.org/10.1182/blood-2025-6406
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-20212025
  2. 2Diagnostic conformity to who criteria and use of cytoreductive therapy in classical myeloproliferative neoplasms: Experience from a resource-limited country2025
  3. 3Non-cancer related deaths in myeloproliferative neoplasm and Myelodysplastic Syndromes : A populaton based analysis2025
  4. 4Myeloproliferative neoplasms in Mexico: An analysis of clinical features, driver mutations, and disease progression patterns in a case series.2025
  5. 5Socioeconomic, racial, and hospital-level disparities in inpatient mortality among patients with plasma cell dyscrasias: A 2016-2022 nationwide analysis from the national inpatient sample2025